Brisbane Local Business
Local business in Brisbane, CA
Yesterday | via The Washington Post
Boehringer Ingelheim GmbH priced its new treatment for a deadly lung-scarring disease at $96,000 a year, just higher than Roche Holding AG's competing product. Both companies last week received U.S. Food and Drug Administration approval for their drugs, bringing the first two treatments to the U.S. market for idiopathic pulmonary fibrosis, a disease that kills 60 percent to 80 percent of patients within five years. Comment?
Wednesday Oct 15 | via Business Journal
New approach to clinical trial helped InterMune win FDA approval for the first FDA-approved treatment for idiopathic pulmonary fibrosis. A treatment for a fatal lung-scarring disease - the center of an $8.3 billion buyout of a Peninsula company by drug giant Roche - won regulatory approval Wednesday. Comment?
Wednesday Oct 15 | via PressReleasePoint
Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration has approved EsbrietA as a treatment for idiopathic pulmonary fibrosis in the United States. IPF is a fatal disease caused by progressive scarring of the lungs, which makes breathing difficult and prevents the heart, muscles and vital organs from receiving enough oxygen to work properly. Comment?
Copyright © 2014 Topix LLC